Mupirocin is the Preferred Topical Antibiotic for Superficial Skin Infections
For superficial skin infections like impetigo when the causative organism is unknown or MRSA is a concern, use mupirocin (Bactroban) as first-line topical therapy. The 2014 IDSA guidelines explicitly recommend topical mupirocin or retapamulin as equally effective as oral antimicrobials for impetigo 1. Mupirocin has specific activity against MRSA, which is critical given the increasing prevalence of community-acquired MRSA in skin infections 2.
Why Mupirocin Over Fusidic Acid (Fucidin)
Guideline Support
The IDSA guidelines specifically name mupirocin for:
- Primary treatment of impetigo - as effective as oral antibiotics 1
- MRSA decolonization - twice-daily intranasal mupirocin for 5 days as part of decolonization regimens for recurrent S. aureus infections 1
Fusidic acid is notably absent from IDSA recommendations, which is significant given these are the authoritative U.S. guidelines for skin and soft tissue infections.
MRSA Coverage
Mupirocin is explicitly active against methicillin-resistant Staphylococcus aureus (MRSA) 2. The FDA label confirms mupirocin's unique mechanism—reversible binding to bacterial isoleucyl-tRNA synthetase—results in no cross-resistance with other antimicrobial classes 2. This is crucial when MRSA is suspected or the organism is unknown.
Clinical Efficacy Data
While older comparative studies (1988-1989) showed similar efficacy between the two agents 3, 4, 5, more recent evidence favors mupirocin:
- A 2025 study demonstrated 99.2% therapeutic response in infected wounds with minimal adverse effects 6
- Mupirocin showed significantly better elimination of S. aureus and beta-hemolytic streptococci (96% vs 88% with fusidic acid) 5
- For acute primary infections and impetigo specifically, mupirocin was significantly more effective (P < 0.01) 5
However, one 2025 study suggested fusidic acid may have broader activity against Propionibacterium acnes 7, though this is less relevant for typical superficial infections.
Practical Application Algorithm
When organism is unknown:
- Use mupirocin 2% ointment applied 3 times daily for 5-7 days
- Covers both S. aureus (including MRSA) and streptococci
When MRSA is specifically suspected or confirmed:
- Mupirocin is the clear choice given explicit MRSA activity 2
- Consider adding systemic MRSA-active antibiotics if SIRS criteria present 1
For recurrent infections:
- Use mupirocin as part of decolonization: intranasal application twice daily for 5 days, combined with chlorhexidine washes 1
Important Caveats
Resistance Concerns
- High-level mupirocin resistance (MIC >1024 mcg/mL) has been reported, mediated by mupA and mupB genes 8
- Resistance remains relatively uncommon but is increasing globally 8
- Reserve mupirocin for appropriate indications to preserve efficacy
Tolerability
- Older studies reported more adverse effects with mupirocin (7.4% vs 1.0% with fusidic acid), primarily complaints about greasiness 3
- However, recent studies show minimal adverse reactions (<1%) 6
- Both agents are generally well-tolerated
Systemic Absorption
- Mupirocin has minimal systemic absorption through intact skin 2
- More frequent percutaneous absorption occurs in children (90%) versus adults (44%), though concentrations remain low and clinically insignificant 2
Bottom Line
Choose mupirocin for empiric treatment of superficial skin infections based on guideline recommendations, proven MRSA activity, and superior bacteriologic cure rates for the most common pathogens. Fusidic acid, while effective, lacks the same level of guideline support and MRSA-specific evidence. The 2014 IDSA guidelines' explicit endorsement of mupirocin for impetigo treatment 1 and MRSA decolonization 1 makes it the evidence-based choice when selecting between these two agents.